EPS for Evofem Biosciences, Inc. (EVFM) Expected At $-0.41

May 4, 2018 - By Nellie Frank

Analysts expect Evofem Biosciences, Inc. (NASDAQ:EVFM) to report $-0.41 EPS on May, 10.They anticipate $0.91 EPS change or 68.94 % from last quarter’s $-1.32 EPS. The stock increased 12.95% or $0.9 during the last trading session, reaching $7.85. About 24,379 shares traded or 98.11% up from the average. Evofem Biosciences, Inc. (NASDAQ:EVFM) has 0.00% since May 4, 2017 and is . It has underperformed by 11.55% the S&P500.

Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. The company has market cap of $139.44 million. The company's product includes, Amphora contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections, and antimicrobial drug product to prevent the reoccurrence of bacterial vaginosis. It currently has negative earnings. It also offers AMPOWER clinical research study, Chlamydia/Gonorrhea prevention clinical trial, and reduction in the recurrence of bacterial vaginosis clinical trial.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.